NASDAQ: ATHE - Alterity Therapeutics Limited

Rentabilité sur six mois: +73%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Alterity Therapeutics Limited


À propos de l'entreprise Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

plus de détails
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

IPO date 2002-09-05
ISIN US02155X1063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://alteritytherapeutics.com
Цена ао 1.45
Changement de prix par jour: -0.2858% (3.149)
Changement de prix par semaine: +42.73% (2.2)
Changement de prix par mois: +188.07% (1.09)
Changement de prix sur 3 mois: +136.98% (1.325)
Changement de prix sur six mois: +73% (1.815)
Changement de prix par an: +26.1% (2.49)
Evolution du prix sur 3 ans: +256.01% (0.882)
Evolution du prix sur 5 ans: +204.85% (1.03)
Evolution des prix sur 10 ans: 0% (3.14)
Evolution des prix depuis le début de l'année: +163.87% (1.19)

Sous-estimation

Nom Signification Grade
P/S 4.09 4
P/BV 1.19 9
P/E 0 0
EV/EBITDA -0.2025 0
Total: 5.38

Efficacité

Nom Signification Grade
ROA, % -82.18 0
ROE, % -104.47 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0081 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 876.58 10
Rentabilité Ebitda, % 89.99 9
Rentabilité EPS, % 31034.18 10
Total: 8.6



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (70 années)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (64 année)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (66 années)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (66 années)
Dr. Steven D. Targum M.D. Chief Medical Advisor

Adresse: Australia, Melbourne, 350 Collins Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://alteritytherapeutics.com